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Abstract
Background: Respiratory distress syndrome (RDS) and feeding intolerance are common conditions in preterm
infants and among the major causes of neonatal mortality and morbidity.
For many years, preterm infants with RDS have been treated with mechanical ventilation, increasing risks of acute
lung injury and bronchopulmonary dysplasia.
In recent years non-invasive ventilation techniques have been developed. Showing similar efficacy and risk of
bronchopulmonary dysplasia, nasal continuous positive airway pressure (NCPAP) and heated humidified high-flow
nasal cannula (HHHFNC) have become the most widespread techniques in neonatal intensive care units. However,
their impact on nutrition, particularly on feeding tolerance and risk of complications, is still unknown in preterm infants.
The aim of the study is to evaluate the impact of NCPAP vs HHHFNC on enteral feeding and to identify the most
suitable technique for preterm infants with RDS.
Methods: A multicenter randomized single-blind controlled trial was designed. All preterm infants with a gestational
age of 25–29 weeks treated with NCPAP or HHHFNC for RDS and demonstrating stability for at least 48 h along with
the compliance with inclusion criteria (age less than 7 days, need for non-invasive respiratory support, suitability to start
enteral feeding) will be enrolled in the study and randomized to the NCPAP or HHHFNC arm. All patients will be
monitored until discharge, and data will be analyzed according to an intention-to-treat model.
The primary outcome is the time to reach full enteral feeding, while parameters of respiratory support, feeding tolerance,
and overall health status will be evaluated as secondary outcomes. The sample size was calculated at 141 patients per arm.
Discussion: The identification of the most suitable technique (NCPAP vs HHHFNC) for preterm infants with feeding
intolerance could reduce gastrointestinal complications, improve growth, and reduce hospital length of stay, thus
improving clinical outcomes and reducing health costs. The evaluation of the timing of oral feeding could be useful in
understanding the influence that these techniques could have on the development of sucking-swallow coordination.
Moreover, the evaluation of the response to NCPAP and HHHFNC could clarify their efficacy as a treatment for RDS in
extremely preterm infants.
Trial registration: ClinicalTrials.gov, NCT03548324. Registered on 7 June 2018.
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Background
Respiratory distress syndrome (RDS) is a common con-
dition in premature infants and one of the major causes
of neonatal mortality [1]. For many years, preterm in-
fants with RDS have been treated with mechanical ven-
tilation, increasing the risks of acute lung injury and
long-term morbidity, such as bronchopulmonary dys-
plasia (BPD) [2–5]. Offering an appropriate respiratory
support in the delivery room, together with early sur-
factant administration, can allow one to avoid or limit
endotracheal ventilation with better outcomes in terms
of mortality and short- and long-term complications,
above all BPD [6]. Early nasal continuous positive air-
way pressure (NCPAP) treatment combined with sur-
factant replacement therapy decreases the need for
mechanical ventilation and has been recommended as
the first line treatment for RDS [7, 8]. However, NCPAP
has significant limitations, mainly related to the type of
interface needed. Excessive leaks around the prongs or
mask and through the mouth can lead to inadequate
support, whereas excessive pressure may result in
pneumothorax and damage to the nose and face. More-
over, the bulky fixation devices obscure the infant’s face,
interfering with both feeding and positioning [9]. In re-
cent years, heated humidified high-flow nasal cannula
(HHHFNC) has been studied as an alternative non-in-
vasive respiratory support (NRS). HHHFNC became
popular partially due to some perceived advantages re-
lated to the type of interface used. Cannulas are easier
to apply than NCPAP prongs or mask, may be more
comfortable for infants, and may enable easier access to
babies’ faces, thus facilitating feeding and parental
bonding [10–12]. Whereas the practical advantages
seem to be established, there is controversy about
HHHFNC efficacy as respiratory support [13–15]. Re-
cent studies support that HHHFNC is as effective as
NCPAP for the primary treatment of RDS, but evi-
dences are still insufficient and data are still lacking, es-
pecially for the extremely preterm population (< 28
weeks’ gestation) [14, 16–18]. A recent Cochrane re-
view comparing HHHFNC with other NRS measures
showed equivalent rates of treatment failure and similar
rates of BPD when used as a post-extubation support in
preterm infants [19]. With equivalent effectiveness, the
choice of the most adequate NRS should consider the
impact on the health status of the premature infant,
evaluating above all the effect on nutrition and growth.
Along with RDS, feeding intolerance (FI) represents a
relevant issue in preterm infants, and the coexistence
of the two represents a great challenge for the neonat-
ologist [20]. Because of gastrointestinal immaturity, a
considerable proportion of premature infants will de-
velop clinical symptoms of FI, causing interruptions of
feeding. This delays the establishment of adequate
enteral nutrition and prolongs the need for parenteral
nutrition, thus increasing the risk of infections and
prolonging hospital stay [21]. Avoiding FI and its com-
plications, such as necrotizing enterocolitis (NEC), is a
priority for the neonatologist, who often faces the chal-
lenge of interpreting the clinical and prognostic signifi-
cance of common and aspecific signs of FI. Clear
identification of the parameters that should be evalu-
ated to identify FI is still lacking in the literature, al-
though, among controversy, the presence of gastric
residuals, vomits and/or regurgitations, and abdominal
distension and the onset of crises of apnea/bradycardia
are considered the most frequent signs [22, 23]. A cor-
relation between non-invasive ventilation and the oc-
currence of FI and NEC is plausible, although the
mechanisms through which ventilation may induce FI
and its incidence in ventilated infants are still unclear
[20, 24]. The most common hypothesis is that pressur-
ized gases that are not completely conveyed to the air-
ways could cause bowel distension. Bowel distension in
infants on CPAP was described by Jaile et al. [25] as
CPAP belly syndrome, but no inferences about feeding
tolerance and risk of NEC were drawn. More recent
studies evaluated the effect of CPAP on mesenteric flow
and gastric emptying, suggesting a role of CPAP as a
risk factor for FI [26–28]. No specific studies have been
designed to evaluate the impact of different types of
NRS on FI and the occurrence of NEC, which are gen-
erally evaluated as secondary outcomes, susceptible to
data analysis and patient selection biases. Our hypoth-
esis is that different techniques of NRS may have differ-
ent impacts on feeding issues in preterm infants.
We therefore intend to compare the application of
NCPAP and HHHFNC in preterm infants with RDS to
evaluate their impact on FI.
Methods
Aims
The aims of the study are to evaluate the effects of
different NRS techniques (NCPAP vs HHHFNC) on
feeding tolerance in preterm infants with RDS and to
evaluate their impact on full enteral feeding (FEF)
achievement and acquisition of oral feeding. A fur-
ther aim is to evaluate the response to NCPAP and
HHHFNC as treatment for RDS in extremely pre-
term infants.
Study design and setting
The study has been designed as a multicenter random-
ized no-mask controlled trial. It will involve the major
Italian neonatal intensive care units (NICUs) and will be
coordinated by the NICU of the University of Turin.
Cresi et al. Trials           (2019) 20:67 Page 2 of 8
Inclusion criteria
All infants admitted to the NICUs with a gestational age
between 25 and 29 weeks and who will have met the
following inclusion criteria will be consecutively enrolled
in the study:
1. Presence of RDS
2. Period of stability on HHHFNC or NCPAP for at
least 48 h in the first 5 days of life (SatO2 TC 90–95%,
pCO2 ≤ 60mmHg, FiO2 < 40%, Silverman score [29]
≤ 6, ≤ 2 apnea episodes/h with CPAP ≤7 cmH2O if
on NCPAP, and flow ≤7 L/min if on HHHFNC)
3. ≤ 7 days of life
4. Suitability to start enteral feeding (if already started
it should be less than 75 mL/Kg/day)
5. Parental written consent
Exclusion criteria
The following are the study exclusion criteria:
1. Neurological or surgical diseases
2. Sepsis
3. Chromosomal abnormalities
4. Major malformations
Recruitment and randomization
Informed written consent will be signed by both parents,
and sufficient time will be allowed for consent.
Non-Italian-speaking parents will only be asked for their
consent if an adult interpreter is available. Trust interpreter
and link worker services will be used to support involvement
of participants whose first language is not Italian.
Eligible patients will be allocated to one of the two
arms (NCPAP or HHHFNC) by block randomization.
A software has been designed to automatically gener-
ate a randomization code and to obtain, in each
research unit, a balance between patients with gesta-
tional age < 28 weeks and ≥ 28 weeks in both arms.
The randomization software will be available for all
research units, on a password-protected platform on
the Enteral Nutrition Tolerance And REspiratory
Support (ENTARES) website, and will generate a
randomization sequence to which all clinicians are
blind.
Monitoring and data collection
Each research unit will adopt its own protocols for clin-
ical management of the patients enrolled in the study
while still respecting some minimal standard criteria
for respiratory support and enteral nutrition, common
for all participating units and defined as follows.
Minimal standard criteria for respiratory support
The suggested initial setup is [30, 31]:
– CPAP between 5 and 7 cmH2O if on NCPAP and
flow between 4 and 7 L/min if on HHHFNC
Table 1 Criteria for the interruption of enteral feeding
Minor criteria Major criteria
Physical examination • Abdominal distension
• Visible bowel ansa
• Abdominal distension responsive to gastric suction/rectal
stimulation
• Dyschromic abdominal wall
• Abdominal distension not responsive to gastric
detension/rectal stimulation
• Painful abdomen
Regurgitations/vomits • ≤ 2 episodes between 2 feeds or in the
previous 3 h (if not fed)
• > 2 episodes between 2 feeds or in the previous
3 h (if not fed)
• Bilious vomiting/hematemesis
Gastric residual volumes (GRVs)a • GRV < 100% of previous feed (bilious or with
hematic fragments)
• Hematic/fecaloidal GRV
• GRV≥ 100% of previous feed
Alvus • Mucous stools • Hematic stools
Cardiorespiratory (CR) events • ≥ 3 CR eventsb/h • ≥ 1 extreme CR eventc
0–1 minor criteria: - Continue enteral feeding with increments
as per protocol (max 30mL/kg/day)
2 minor criteria: - Stop increasing feeds, re-assess prior to the next
feed, and evaluate GRV if not done before
- If 2 minor criteria in at least 2 consecutive
evaluations, consider reducing volume of feed
1 major criterion or 3 minor
criteria:
- Interrupt enteral feeding and re-assess prior
to the next feed
aThe evaluation of GRVs is elective and according to the protocol of each research unit. GRVs are considered pathological according to minor and major criteria
bCR events were defined as episodes of apnea lasting more than 20 s or more than 5 s if followed by desaturation or bradycardia, episodes of desaturation with
blood oxygen saturation below 80%, and episodes of bradycardia with heart rate below 80 beats per minute
cExtreme CR events were defined as CR events requiring resuscitation
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– FiO2 set to reach pO2 = 50–60mmHg (capillary/
arterial blood gas test) and SatO2 TC = 90–95%
The criteria to try weaning are [30, 31]:
– CPAP < 4 cmH2O if on NCPAP and flow < 2 L/min
if on HHHFNC
– FiO2 < 25% to maintain pO2 = 50–60mmHg (capillary/
arterial blood gas test) and SatO2 TC = 90–95%
The failure criteria are [30, 31]:
– FiO2 > 40%
– pH < 7.2
– pCO2 > 65mmHg
– ≥ 3 episodes of desaturations (SatO2 TC ≤ 80%) per
hour
– ≥ 3 episodes of apnea (> 20 s) and/or bradycardia
(FC ≤ 80 beats per minute (bpm)) per hour
– Silverman score [29] > 6
Minimal standard criteria for enteral nutrition
The decision to increase volume of feeds will be up
to the clinicians and in accordance with the protocol
used in their own NICU; however, a maximum
cut-off for feeding progression was set at 30 mL/kg/
day [32, 33].
The indications for the interruption of feeding are
based on abdominal examination, the occurrence of
vomits/regurgitations and cardiorespiratory events, and
the evaluation of alvus and gastric residual volumes
(evaluated if required by the protocol in use) as detailed
Table 2 Abdominal distension score
Extent of distension Score
Abdomen is not distended 0
Abdomen is distended but not tense 1
Abdomen is distended and tense, responsive to
gastric suction/rectal stimulation
2
Abdomen is distended and tense, not responsive
to gastric detension/rectal stimulation
3
Table 3 Data recorded during the study period
Ventilation/respiration parametersa
– Respiratory support technique
– PEEP/CPAP (cmH2O)
– Peak inspiratory pressure (PIP, cmH2O)
– Flow (L/min)
– FiO2 (%)
– Respiratory rate (acts/min)
– Transcutaneous O2 blood saturation (SatO2 TC %)
– Capillary/arterial blood gas test
– Episodes of apnea (> 20 s or > 5 s if followed by bradycardia/
desaturation), bradycardia (Heart rate≤ 80 bpm) and desaturation
(SatO2 TC≤ 80%)/day
– Silverman score
Feeding parametersb
– Parenteral nutrition intake (mL/kg/day)
– Enteral nutrition intake (mL/kg/day)
– Total caloric intake (Kcal/kg/day)
– Type of milk: human milk or formula
– Modality of feeding (bolus, gavage, continuous feeding)
– Modality of fortification (if any; type of fortifier: standard, target, or
adjustable fortification)
– Enteral feeding interruptions (episodes/day)
– Not given feeds (episodes/day)
– Pathologic gastric residual volumes (episodes/day)
– Vomits and/or regurgitations (episodes/day)
– Abdominal distention (medium score/day)
Auxological parametersc
– Weight (g)
– Length (cm)
– Cranial circumference (cm)
Overall health status parametersd
– Patent ductus arteriosus
– Intraventricular hemorrhage
– Leukomalacia
– Retinopathy of prematurity
– Pneumothorax
– Blood transfusion
– NEC
– Intestinal perforation
aVentilation/respiration parameters will be recorded at enrollment, at
achievement of half enteral feeding and full enteral feeding, at the beginning
of oral feeding, at achievement of full oral feeding, and at any change in
respiratory assistance strategy. Apnea monitoring will extend until any
respiratory support is needed (except for O2 supplementation per
nasal cannula)
bFeeding parameters will be recorded daily until full enteral feeding is
achieved, at the beginning of oral feeding, at achievement of full oral feeding,
and at any change in respiratory assistance strategy
cAuxological parameters will be recorded at the time of enrollment, upon
achieving half enteral feeding and full enteral feeding, and at discharge
dRelevant clinical events/diagnosis will be recorded from enrollment
until discharge
Table 4 Secondary outcomes
– Time to reach HEF, defined as an enteral intake of 75 mL/Kg/day
(days)
– Interruptions of enteral feeding (episodes/day)
– Not given feeds (episodes/day)
– Pathologic gastric residual volumes (episodes/day)
– Vomits and/or regurgitations (episodes/day)
– Abdominal distention (mean score/day)
– Beginning of oral feeding (post-menstrual age)
– Time to reach full oral feeding (number of days)
– Post-menstrual age at full oral feeding (weeks)
– Weight growth (Δ z-score)
– Duration of the respiratory support assigned at randomization
(days)
– Total duration of respiratory support need (days)
– Failure of the respiratory support assigned at randomization (yes/
no)
– Length of hospital stay (days)
– Duration of central venous catheter (days)
– Clinical events and complications (NEC, bowel perforation,
pneumothorax, BPD, PDA, ROP, IVH, PVL)
– Transfers to other hospitals or deaths before reaching full enteral
feeding (number of patients)
HEF half enteral feeding, NEC necrotizing enterocolitis, BPD bronchopulmonary
dysplasia, PDA patent ductus arteriosus, ROP retinopathy of prematurity, IVH
intraventricular hemorrhage, PVL periventricular leukomalacia
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in Table 1 [22, 34, 35]. A score system was developed
to evaluate abdominal distension (Table 2).
Data on respiratory support, nutrition, growth, and
overall clinical status will be collected from enroll-
ment to discharge. According to an intention-to-treat
model, each patient will be monitored whatever the
occurring clinical events, including the failure of the
modality of respiratory support assigned at enroll-
ment. Death or transfer to another hospital before
reaching FEF will be the only reasons for a patient to
drop the study.
All data to be collected will be obtained from the clin-
ical records. Data will be recorded on a common data-
base available on the ENTARES website and specifically
designed for this study. Access to the database will be
password protected, and data will be entered by the local
principal investigator. Participants will be identified by
trial number only.
Fig. 1 Design of the study
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All data recorded throughout the study period are
listed in Table 3.
Outcomes
The primary outcome of the study is the time
needed to reach FEF, defined as an enteral intake of
150 mL/Kg/day. Secondary outcomes are listed in
Table 4.
The design of the study is outlined in Fig. 1. The
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) figure of enrollment, inter-
ventions, and assessments is shown in Fig. 2. The
SPIRIT checklist is provided as Additional file 1.
Statistical analysis and sample size
Time to reach FEF, the primary outcome, will be ana-
lyzed by Kaplan and Meier survival analysis according to
the intention-to-treat principle. The two arms will be
compared with the log-rank Test [36].
Regarding secondary outcomes, the time to reach half
enteral feeding and time to reach full oral feeding will be
estimated by Kaplan and Meier analysis, the failure
of the respiratory support assigned at randomization
will be compared using Fischer’s exact test, and the
other secondary outcomes will be estimated using
appropriate generalized linear models. This will be a
single-blind trial where the blinded person will be
the statistician.
Based on a population of infants with a gestational age
< 30 weeks who are consecutively admitted to the NICUs
of each research unit from January to June 2017 (mean
time of FEF 19.6 days) and considering a ratio between
the subjects of the two arms of 1:1, a sample size of at
least 141 patients per arm has been calculated to observe
a difference of 30% between the two arms (5.7 days).
An interim analysis is planned upon reaching the en-
rollment of half of the patients expected by the sample
size calculation.
Fig. 2 SPIRIT figure
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Quality control and quality assurance procedures
Compliance to protocol
Compliance will be defined as full adherence to proto-
col. Compliance with the protocol will be ensured by a
number of procedures as described below.
Site setup
Local principal investigators participated in preparatory
meetings in which details on study protocol, non-inva-
sive ventilation and feeding strategies, and data collec-
tion were accurately discussed. All units received
detailed written instruction on web-based recording
data, and to resolve possible difficulties it will be pos-
sible to contact the Clinical Trials Coordinating Unit
(Dr. E Maggiora and Dr. SM Borgione).
Safety
Safety endpoints will include incidence, severity, and
causality of reported significant adverse events (SAEs).
All SAEs will be followed until satisfactory resolution
or until the investigator responsible for the care of the
participant deems the event to be chronic or the patient
to be stable. All expected and unexpected SAEs,
whether or not they are attributable to the study inter-
vention, will be reviewed by the local principal investi-
gators to determine if there is a reasonable suspected
causal relationship with the intervention. If the rela-
tionship is reasonable, SAEs will be reported to the
chief investigators, who will then report them to the
ethics committee and inform all other investigators to
guarantee the safety of the participants.
Discussion
The identification of the most suitable NRS technique
for preterm infants with RDS and FI could reduce
gastrointestinal complications, improve growth, and re-
duce hospital stay, thus improving quality of life of in-
fants and their family and reducing health costs.
The evaluation of the timing of oral feeding could be
useful in understanding the influence that NRS tech-
niques have on the development of sucking-swallowing
coordination.
A standard protocol for the suspension of feeding will
be proposed along with a new clinical score to evaluate
signs of FI. It may be useful to evaluate the influence,
on clinical practice and on the time of achievement of
FEF, of the application of a defined and shared method
for the evaluation of feeding tolerance. The authors
considered a difference of 30% in the time to reach FEF
between the groups as the minimum needed to observe
a clinically relevant effect. As a consequence, the sam-
ple of this study was set at 141 patients per arm.
The evaluation of the response to NCPAP and
HHHFNC could clarify their efficacy as treatment for
RDS in extremely preterm infants.
Trial status
The protocol is version no. 1, 24 April 2018. The re-
cruitment will begin after approval by the ethics com-
mittee of all research units and is expected to begin on
15 September 2018. The time expected to complete the
recruitment is about 2 years.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 121 kb)
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